SCHEMBL292834

SCHEMBL292834

COc1ccc(COC(=O)OCc2ccc(OC)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.60
HTT P42858 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.56
NPC1 O15118 1/20 0.56
POLB P06746 1/20 0.56
RAB9A P51151 1/20 0.56
IDO1 P14902 2/20 0.55
AGXT P21549 2/20 0.55
MMP9 P14780 2/20 0.54
MMP1 P03956 1/20 0.54
LDHA P00338 1/20 0.53
FFAR1 O14842 1/20 0.53
MMP2 P08253 1/20 0.53
MMP12 P39900 1/20 0.53
F2RL1 P55085 1/20 0.52
MAPT P10636 1/20 0.51
ATM Q13315 1/20 0.51
FABP7 O15540 1/20 0.51
FABP5 Q01469 1/20 0.51
P2RX4 Q99571 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6644102 0.93 LTA4H (0.58) ALDH1A1HTTSMN1; SMN2NPC1POLB
SCHEMBL22028109 0.93 LTA4H (0.58) ALDH1A1HTTSMN1; SMN2NPC1POLB
SCHEMBL13034049 0.93 ALDH1A1 (0.54) ALDH1A1HTTSMN1; SMN2NPC1POLB
SCHEMBL697621 0.92 ALDH1A1 (0.61) ALDH1A1HTTSMN1; SMN2NPC1POLB
SCHEMBL6366124 0.92 ALDH1A1 (0.57) ALDH1A1HTTSMN1; SMN2NPC1POLB
SCHEMBL698136 0.91 ALDH1A1 (0.53) ALDH1A1HTTSMN1; SMN2NPC1POLB
SCHEMBL697620 0.89 ALDH1A1 (0.54) ALDH1A1HTTSMN1; SMN2NPC1POLB
SCHEMBL3758807 0.88 ALDH1A1 (0.60) ALDH1A1HTTSMN1; SMN2NPC1POLB
SCHEMBL159668 0.87 SMN1; SMN2 (0.50) ALDH1A1HTTSMN1; SMN2NPC1POLB
SCHEMBL112518 0.86 ALDH1A1 (0.62) ALDH1A1HTTSMN1; SMN2NPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1329 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260035402-A1 C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF ZIKANI THERAPEUTICS INC (US) 2026-02-05 US claimed
US-12060334-B2 3-substituted phenazine derivatives as antimicrobial agents UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2024-08-13 US claimed
US-11634449-B2 Macrolides and methods of their preparation and use PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2023-04-25 US claimed
EP-3649135-B1 SYNTHESIS OF HALICHONDRINS HARVARD COLLEGE (US) 2022-12-28 EP claimed
US-20220332747-A1 MACROLIDES AND METHODS OF THEIR PREPARATION AND USE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2022-10-20 US claimed
EP-3291676-B1 MITRAGYNINE ANALOGS AND USES THEREOF MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2022-08-17 EP claimed
US-11241435-B2 Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis THE GENERAL HOSPITAL CORPORATION (US) 2022-02-08 US claimed
EP-3172213-B1 MACROCYCLIC KINASE INHIBITORS AND USES THEREOF DANA FARBER CANCER INST INC (US) 2021-09-22 EP claimed
EP-3171874-B1 IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF DANA FARBER CANCER INST INC (US) 2020-11-18 EP claimed
EP-3063164-B1 SYNTHETIC ROUTE TO 2'-DEOXY-2',2'-DIFLUOROTETRAHYDROURIDINES OTSUKA PHARMA CO LTD (JP) 2018-12-05 EP claimed
EP-2727915-B1 Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof CONCERT PHARMACEUTICALS INC (US) 2016-04-13 EP claimed
EP-2727915-A1 Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof Concert Pharmaceuticals Inc. (US) 2014-05-07 EP claimed
US-12637463-B2 Tricyclic kinase inhibitors and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2026-05-26 US disclosed
US-12637453-B2 Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2026-05-26 US disclosed
US-20260137806-A1 INTERCALATING SUGAR MOLECULES XALUD THERAPEUTICS, INC. (US) 2026-05-21 US disclosed
WO-2026107134-A1 USE OF SMALL MOLECULE GLUTAMINASE INHIBITORS FOR TREATING AGE-RELATED DISORDERS LEAL THERAPEUTICS, INC. (US) 2026-05-21 WO disclosed
EP-0975632-A1 ALKALOID HALIDE SALTS OF SWAINSONINE AND METHODS OF USE Glycodesign Inc. (CA) 2000-02-02 EP disclosed
WO-1998046602-A1 ALKALOID HALIDE SALTS OF SWAINSONINE AND METHODS OF USE GLYCODESIGN INC. (CA) 1998-10-22 WO disclosed
WO-1997026873-A1 ANTIMICROBIAL AURONE DERIVATIVES PHYTERA, INC. (US) 1997-07-31 WO disclosed
US-3856848-A PROCESS FOR PREPARING A PROTECTED ARGININE LILLY CO ELI 1974-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12637463-B2 Tricyclic kinase inhibitors and uses thereof CDK1, CDK11A, CDK11B ALDH1A1 2753/4885HTT 2980/4885SMN1; SMN2 2356/4885
US-20260035402-A1 C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF MALT1, CCR10, CYP51A1 ALDH1A1 1752/4885HTT 2466/4885SMN1; SMN2 2710/4885
US-20220332747-A1 MACROLIDES AND METHODS OF THEIR PREPARATION AND USE CYP11B2, ERG28, DHCR7 ALDH1A1 1071/4885HTT 2188/4885SMN1; SMN2 1755/4885
US-11634449-B2 Macrolides and methods of their preparation and use CYP11B2, ERG28, DHCR7 ALDH1A1 1071/4885HTT 2188/4885SMN1; SMN2 1755/4885
US-11241435-B2 Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis SOST, SIK2, SIK1 ALDH1A1 4790/4885HTT 3638/4885SMN1; SMN2 3838/4885
US-20260137806-A1 INTERCALATING SUGAR MOLECULES SLC2A1, SLC2A2, SLC2A4 ALDH1A1 542/4885HTT 1019/4885SMN1; SMN2 690/4885
US-12637453-B2 Pyrazolopyridine inhibitors of c-Jun-n-Terminal kinases and uses thereof MAP3K1, MAP3K3, MAPK1 ALDH1A1 1172/4885HTT 3174/4885SMN1; SMN2 3802/4885
US-12060334-B2 3-substituted phenazine derivatives as antimicrobial agents ROS1, NOX4, NOX5 ALDH1A1 348/4885HTT 3058/4885SMN1; SMN2 4864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.